Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide

Semaglutide has been the heavyweight in research circles for metabolic health. Now, Hoth Therapeutics just dropped some head-turning data. Their HT-VA research collaboration found that GDNF—a protein, not a classic peptide—reprograms liver fat metabolism and outperforms semaglutide in early models.

Here’s what matters: GDNF didn’t just tweak a few numbers. It shut down the gene responsible for creating new fat in the liver. At the same time, it switched on fat-burning pathways, delivering a metabolic one-two punch researchers are chasing. This effect was stronger than what semaglutide achieved in the same setting.

Key details from the study:

Why care? Semaglutide is already a benchmark for GLP-1 research peptides. Any compound beating it in metabolic readouts deserves a closer look. But this isn’t about replacing semaglutide—think of it as expanding the metabolic toolkit. Researchers now have another lever for targeting liver fat regulation, which could mean new angles for exploring obesity, NAFLD, and metabolic health.

For those tracking where to source research peptides like semaglutide, check the semaglutide page and our vendor directory for up-to-date listings.

Bottom line: GDNF just gave metabolic researchers a new direction. Semaglutide’s still a powerhouse, but the competition is getting interesting.